Again, you need to look at the morbidity numbers, which are produced and readily available. You are misinterpreting the CDC statistics.I want to apologize for my earlier tone. It came off a lot more harsh than intended. Way, WAY more harsh than intended.
That said, the statistics you are citing have a lot of issues. The Payne, et al study only found 8 incidents for those aged 4-13 across 7 states. They then extrapolated that into the number you gave by multiplying it by the true number of 4-13 year old kids infected. That would be fine if we knew that number, but we don't and the models estimating that number vary wildly. The researchers could pick whatever study they wanted. The one they chose was from 18 months ago, and the only reason I can imagine for picking a study that old was because it gave numbers that hiked the per-1m number the most.
The bottom line is this, in that study they only found 8 incidents in an huge population that included New York, New Jersey, Michigan, Pennsylvania, Massachusetts, Georgia, and Connecticut. In the vaccine trials given to only 2,200 kids, they came up with 9 incidents. What will happen when the vaccine is given to millions of kids? I don't know but I am going to sit back and watch before I line my kid up for that shot. Myocarditis is the dangerous part of MIS-C so this very much is apples-to-apples.
If you have young kids, you see those statistics, and you still want to inject your kid then I won't stand in your way or disparage you. If you don't have young kids but instead want to use your franchise to get the government to do that to my kid against my will, then we're going to have some words.
The CDC experts expect 56-69 cases of myocarditis per 1MM male children aged 12-17 vaccinated. These same vaccinations will prevent 215 COVID-19 hospitalizations per 1 Million Doses, 71 ICU admissions, and 2 deaths. And this does not include the expected 336 cases of MIS-C caused after COVID-19 infection. Keep in mind that these numbers are calculated as +/- 10% of crude VAERS reporting rates, and include cases of myocarditis, pericarditis, and myopericarditis. The analysis evaluated direct benefit and harm, per million second doses of mRNA COVID-19 vaccine given in the applicable age group over 120 days.
Because of this clear and convincing data, the Advisory Committee on Immunization Practices concluded that the benefits of the COVID-19 vaccination to individual persons at the population level clearly outweighed the risks of myocarditis after vaccination.
Directly from the CDC Morbidity and Mortality Week Report on this issue: "Continued use of mRNA COVID-19 vaccines in all recommended age groups (referencing report regarding children) will prevent morbidity and mortality that far exceed the number of cases of myocarditis expected"
For children with COVID-19, the risk of myocarditis is 37 times higher for children under 16 compared to those uninfected.
And finally, while more data will come in, most researches believe the higher risk in older male children is tied to puberty and increased testosterone production, which has been confirmed previously in animal studies, which actually leads to a lower risk for males under 12, which is consistent with Pfizer's report that serious adverse events was less than 2 in 1000, with all adverse events found to be unrelated to the vaccine.